Skip to content

Demonstrating the Diagnostic Power of an Electronic Nose: Study on Exhaled Air Samples

Demonstrating the Diagnostic Power of an Electronic Nose: Pilot Study on Exhaled Air Samples

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03721042
Acronym
OLFADIAG
Enrollment
68
Registered
2018-10-26
Start date
2018-10-11
Completion date
2020-10-01
Last updated
2022-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Gastric Cancer, Pneumological Cancer, Urologic Cancer

Brief summary

The investigators don't know yet how the nose and the brain decode the smells. Scientific studies in neuroscience have shown that people who have tumors may have changes in the smell of secretions. Dogs are extremely efficient at detecting these changes, even before imaging studies. A review of the recent literature shows the different work done on the diagnosis of dogs on human pathologies, especially oncology. It is now known that the smell of exhaled gases is representative of the intestinal biotope and that a large number of pathologies are related to the type of microbial populations that inhabit the intestines. Copying the olfactory organs could thus be of major interest for the early diagnosis of pathologies. More and more works are interested in the diagnostic power of electronic noses. From a technical point of view, these are nano-sensors that mimic the olfactory receptors from the breath gas of the subjects. They analyze the molecules present and compare them with a database to establish a diagnosis according to a probabilistic algorithm. The use of exhaled air for the diagnosis of cancerous pathologies has already been the subject of scientific work. A classification using the SVM (support vector machine) method using data from 320 sensors made it possible to differentiate patients with lung cancer from controls in 98.8% of cases. The differential diagnosis of obstructive bronchopneumopathy was also very well done in this same study. Another study shows equally encouraging results, highlighting sensitivities and specificities above 80%.

Interventions

DEVICEolfactory measuring device

Patients blowing into bags then analysis by olfadiag system

Sponsors

University Hospital, Montpellier
CollaboratorOTHER
Nouvelle Clinique Bonnefon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient must have signed the free and informed consent form or their guardian if applicable. If the state of health of the patient does not allow him to give and sign his consent, it will be sought from the person of trust * The patient must be an affiliate or beneficiary of a health insurance plan * The patient is at least 18 years old

Exclusion criteria

* The patient participates or has participated within 3 months in another study that may have modified their intestinal biotope * The patient is in an exclusion period determined by a previous study * The patient is under the protection of justice * The patient or guardian or trusted person refuses to sign the consent * The patient does not read the French language fluently * The patient claims to be pregnant * The patient is breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
positive predictive value and negative predictive value18 monthspositive predictive value and negative predictive value of the electronic nose

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026